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Abstract
Objective: Black gay, bisexual, and other men who have sex with men (BMSM) are at elevated 
risk for HIV infection in the United States. BMSM who inject drugs may be face even higher HIV 
risk.
Methods: Random time-location sampling was used to survey BMSM attending Black Pride 
events in 6 U.S. cities about HIV risk and protective behaviors, including injection drug use, prior 
HIV testing, and pre-exposure prophylaxis (PrEP). 3,429 individuals who reported a HIV negative/
unknown serostatus at enrollment were included in the analysis. HIV status was determined by in-
field rapid HIV testing.
Results: 3.6% of BMSM had injected drugs in their lifetime and 58.5% of BMSM who had 
injected drugs reported sharing syringes in the past six months. BMSM who had injected drugs 
more commonly reported current PrEP use than BMSM who had never injected (32.5% vs. 8.2%, 
p<0.001). BMSM who had injected drugs were 3.6-fold (95% CI: 2.4, 5.4) more likely to report 
currently using PrEP than BMSM who had never injected after adjustment for sociodemographic, 
substance use, and sexual risk characteristics. Among BMSM who reported ever injecting drugs 
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(n=123), 31.7% tested HIV positive. HIV prevalence did not differ by self-reported PrEP use 
among BMSM who had injected drugs (p=0.59).
Conclusions: BMSM who inject drugs who reported currently using PrEP were no less likely to 
test positive for HIV than those who did not use PrEP. Wrap-around services to support consistent 
PrEP use and long-acting PrEP formulations may improve the effectiveness of PrEP among 
BMSM who inject drugs.
Graphical abstract
1. INTRODUCTION
People who inject drugs (PWID) are at increased risk for human immunodeficiency virus 
(HIV) when they share syringes and other injection equipment (Wejnert, 2016; Spiller et al., 
2015). According to the U.S. Centers for Disease Control and Prevention (CDC, 2017), 1 in 
10 new HIV infections in the U.S. in 2017 were among PWID.4 Gay, bisexual, and other 
men who have sex with men represented 33.9% (1174/3461) of new HIV diagnoses among 
PWID (i.e., PWID-MSM), and PWID-MSM who are Black accounted for 263/1174 (22.4%) 
infections among all PWID-MSM.
To reduce HIV incidence among PWID-MSM, it is imperative that this group has access to a 
combination of harm reduction (e.g., condoms and sterile syringes) and biomedical HIV 
prevention resources (i.e., pre-exposure prophylaxis [PrEP]) that address both sexual- and 
injection-related risks in tandem. PrEP is an efficacious once-daily oral antiretroviral 
medication used to prevent HIV acquisition among HIV-negative individuals. Recent 
increases in injection drug use and high HIV incidence and prevalence among Black MSM 
(BMSM) relative to all other demographic groups, underscore the urgency with which new 
and innovative strategies to increase access to, and adoption of, HIV prevention strategies 
among BMSM, (del Rio, 2016; Matthews et al., 2016), including BMSM who inject drugs, 
are needed.
While several prior studies have explored HIV risk broadly among MSM and MSM who 
inject drugs (Nerlander et al., 2018; Burt & Thiede, 2014) few have characterized injection-
related HIV risk among BMSM who inject drugs. The prevalence of injection drug use 
among BMSM and the prevalence of undiagnosed HIV infection among BMSM who inject 
drugs remain unknown. However, BMSM face the highest lifetime risk of HIV of any U.S. 
racial/ethnic group (Hess et al., 2017), and HIV risk among BMSM who inject drugs may be 
even greater. With current trends, 1 in 2 BMSM could be diagnosed with HIV in their 
lifetime, by contrast, non-Hispanic white MSM face a 1 in 11 chance.10 BMSM who inject 
drugs may face an even higher risk for HIV infection relative to their counterparts who do 
not inject drugs given “risk multiplexity” 11 from their overlapping drug use and sexual risk 
factors. BMSM who inject drugs may also have additional HIV prevention and other 
physical, sexual, and mental health needs distinct from BMSM who do not inject drugs, such 
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as the need for approaches that address sex-, injection-, and overdose-related risks in 
combination (Felsher & Koku, 2018).
Our study had three primary objectives that we evaluated among a sample of BMSM who 
attended Black Pride events in six U.S. cities: Atlanta, GA, Detroit, MI, Houston, TX, 
Memphis, TN, Philadelphia, PA, and Washington, D.C. who reported a HIV negative or 
unknown status prior to study enrollment. First, we characterized injection drug use and 
syringe sharing prevalence. Second, we compared self-reported current PrEP use at the time 
of study participation, HIV testing history, sexual risk behaviors, and results of in-field HIV 
testing between BMSM who injected drugs and BMSM who had never injected drugs. 
Finally, we explored whether self-reported current PrEP use was associated with HIV test 
results during study participation among a sub-sample of BMSM who had injected drugs.
2. METHODS
2.1 Participants and Procedures
Data from the current study were collected by the Promoting Our Worth, Equality, and 
Resilience (POWER) Study Team. The study included a serial cross-sectional survey 
assessment conducted at Black Pride events occurring from 2014–2017 in Atlanta, GA, 
Detroit, MI, Houston, TX, Philadelphia, PA, Memphis, TN, and Washington, D.C. Full study 
procedures and eligibility criteria are described elsewhere (e.g., Friedman et al., 2019; Eaton 
et al., 2017). In brief, at each Black Pride, the POWER Study Team identified official events 
and randomly selected events for recruitment. For each recruitment event, an intercept zone 
was established. As individuals entered the intercept zone, they were counted, approached, 
and invited to participate in the study. In total, 13,396 individuals were approached. 
Individuals were eligible to participate if they (1) were aged 18 years of age or older, (2) 
identified as male or transgender female, and (3) reported having a male sex partner in their 
lifetime. Individuals interested in study activities were screened via electronic tablet for 
eligibility (N=6,015), and 97.4% of those who were eligible provided informed consent and 
completed an audio computer-assisted self-interview (ACASI) survey (N=5,857) which took 
approximately 20 minutes to complete. Participants were then offered in-field confidential 
HIV testing, counseling and referral by a partnering local community-based organization in 
private locations (i.e., mobile testing vans). Testing kits varied by agency and included 
Oraquick (OraSure Technologies, Inc., Bethlehem, PA), Clearview STAT-PAK (Alere Inc., 
Waltham, MA), and INSTI (bioLythical Laboratories, Richmond, BC) HIV tests. 
Participants who declined confidential HIV testing could elect to provide an anonymous 
saliva sample for HIV testing for surveillance purposes only. Participants were compensated 
$10 for survey completion and an additional $10 for HIV testing. All study procedures were 
approved by the University of Pittsburgh Institutional Review Board.
For the present study, participants who reported living with HIV (N=1,006), identified as 
transgender (N=152), did not identify as Black (N=217), completed the survey more than 
once (N=294), or had missing data for variables of interest, including those who chose not to 
take an HIV test (N=759), were removed from analyses. The final, analytic sample size 
included 3,429 participants.
Maksut et al. Page 3














2.2.1. Sociodemographic Characteristics.—Participants reported their age and 
annual income. Annual income was dichotomized as $0-$29,999 and $30,000 and above.
2.2.2. Drug Use Factors.—Participants reported whether they ever used opioids 
(including heroin or misuse of prescription opiates [e.g., Vicodin, Oxycontin]), 
methamphetamine, and cocaine in their lifetime (by any mode of use). Participants who 
reported ever injecting drugs also reported whether they shared syringes in the last six 
months.
2.2.3. HIV Testing Factors.—Participants reported whether they had been tested for 
HIV in the six months before study participation. In addition, we summarized HIV test 
results from in-field testing during study participation. All participants self-reported HIV 
negative or HIV unknown statuses prior to testing.
2.2.4. Sexual Risk Practices Factors.—Participants reported the number of male and 
female partners they had in the past 12 months.
2.2.5. PrEP Awareness and Use Factors.—Participants were asked the following 
about PrEP use: “Have you ever heard of PrEP (pre-exposure prophylaxis)? PrEP is when 
HIV-negative people take anti-HIV medications (antiretrovirals like Truvada) BEFORE 
HAVING SEX to prevent HIV infection.” and “Are you currently taking anti-HIV 
medications (PrEP) to prevent HIV infection?” Participants were categorized into one of the 
following groups: unaware of PrEP, aware but not currently using PrEP, and aware and 
currently using PrEP.
2.3 Data Analysis
We summarized the prevalence of ever injecting drugs by study location and examined 
differences in age, annual income, prevalence of drug use, HIV testing in the past six 
months, sexual risk behaviors, PrEP awareness and current use, and in-field HIV test results 
between BMSM who had injected drugs vs. BMSM who had never injected drugs using 
Chi-squared and Wilcoxon rank sum tests. We estimated the association (prevalence ratio) 
between lifetime injection drug use status and current PrEP use adjusted for demographic 
characteristics, lifetime use of opioids, methamphetamine, and cocaine, and sexual risk 
practices using Poisson generalized estimating equations with robust standard errors Zou et 
al., 2014). Among BMSM who had injected drugs, we characterized whether self-reported 
current PrEP use was associated with participants’ in-field HIV test result. IBM SPSS 
Statistics version 24.0 (SPSS Inc., Chicago, IL) was used for all analyses.
3. RESULTS
Overall, 3.6% (n=123) of the sample reported injecting drugs in their lifetime. Of the 
individuals who reported ever injecting drugs, over half reported sharing syringes in the past 
six months (Table 1). In addition, one quarter of participants tested positive for HIV in-field.
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Relative to BMSM who had never injected drugs, BMSM who had injected drugs were more 
likely to report using opioids, methamphetamine, and cocaine (Table 1). In addition, BMSM 
who had injected drugs were older and had lower annual incomes than BMSM who had 
never injected. BMSM who had injected drugs differed from those who had not injected 
drugs with respect to median number of male or female sexual partners in the last year.
In bivariate analysis, BMSM who had injected drugs were more likely to self-report current 
use of PrEP than BMSM who had never injected drugs. Lifetime injection drug use status 
remained statistically significantly related to current PrEP use when controlling for age, 
annual income, lifetime use of opioids, methamphetamine, and cocaine, and number of male 
and female partners in the past year (Table 2). BMSM who had injected drugs in their 
lifetime were 3.6-fold more likely than those who had never injected drugs to report 
currently using PrEP.
Among the 123 BMSM who had injected drugs, we found no difference in HIV positivity by 
those individuals who self-reported current PrEP use. In addition, while one third of PWID-
MSM reporting PrEP use tested HIV-positive, three in 10 PWID-MSM not reporting PrEP 
tested HIV-positive. Furthermore, current use of PrEP was reported in slightly more than one 
third of PWID-BMSM participants testing positive for HIV.
4. DISCUSSION
The present study described how injection drug use related to HIV infection, PrEP 
awareness and use, and injection-related HIV risk behaviors among a sample of BMSM 
recruited at Black Pride events in six US cities, a population at potentially elevated risk for 
HIV. We observed an alarmingly high level of unknown HIV infection among this sample, 
with only moderate levels of HIV testing in the past six months and PrEP awareness. PrEP 
use was more common among BMSM who injected drugs than those who had not. However, 
the finding that BMSM who injected drugs and used PrEP were just as likely to have an 
unknown HIV infection as those who had not used PrEP suggests that the particular PrEP 
use behaviors in these participants may be insufficient to prevent HIV infection. Our 
findings reflect challenges to HIV status awareness among BMSM and support the need for 
better, more accessible testing strategies and prevention options, including PrEP for these 
communities.
While prior research has indicated that BMSM have a lower prevalence of injection drug use 
than MSM of other races/ethnicities, estimating the burden of injecting behaviors among 
BMSM, along with understanding the HIV prevention needs of BMSM, is important given 
the current backdrop of the opioid crisis. It is especially noteworthy that recent increases in 
overdose mortality, particularly from synthetic opioids (i.e., fentanyl), are growing at faster 
rates among Black versus White racial/ethnic groups, justifying our contemporary evaluation 
of the HIV prevention needs of BMSM who inject drugs (NIDA, 2017).
The present study found that self-reported current use of PrEP was not associated with a 
lower likelihood of a positive in-field HIV test result among men with a history of injection 
drug use and who reported that they were HIV-negative or did not know their HIV-status 
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before study participation. This finding highlights the possibility of PrEP adherence 
challenges and underscore the shortcomings of our current infrastructure to support daily 
regimens of oral PrEP. Future research may consider whether forthcoming long-acting 
formulations of PrEP (e.g., implant, injectable PrEP; Greene et al., 2017) may be more 
acceptable to and better suit the needs of individuals who inject drugs. Indeed, recent data 
suggest that BMSM find injectable PrEP formulations to be as acceptable as oral pills, and 
injectable PrEP may be more manageable than daily oral PrEP (Greene et al., 2017; Biello et 
al., 2018). In addition, future examination of where BMSM who inject drugs obtain PrEP 
may be warranted, as nonmedical sources of PrEP (e.g., friends, romantic and/or sexual 
partners) may come without counseling about when and how often to take PrEP.
The results of the present study underscore the need and benefits of partnering with Black 
Pride events to better develop how, when, and where to offer HIV prevention and risk 
reduction services. Our results suggest that not providing these services at Black Pride 
events may be a significant missed opportunity for risk reduction and health promotion 
efforts for BMSM, including BMSM who inject drugs (Nerlander et al., 2017). In addition, 
syringe services programs and referrals to medication-assisted treatments (MAT) for opioid 
use disorder may be well-suited to offer alongside existing HIV prevention and care 
services, including services offered at Black Pride events. Researchers, policymakers, and 
service providers working for BMSM who inject drugs in these areas should explore the 
potential benefits of integrated HIV prevention and other services (e.g., housing assistance) 
for BMSM who inject drugs.
4.1 Limitations
The findings from the current study need to be interpreted considering the following points. 
BMSM were recruited from Black Pride events in metropolitan areas in the U.S., limiting 
the generalizability of the results to urban rather than rural BMSM populations, as well as 
BMSM who would attend such events. In addition, each participant’s data were collected 
from a single time point; therefore, significant relationships were correlative in nature and 
no temporal associations could be determined. Moreover, while we were able to characterize 
the proportion of BMSM who had injected drugs during their lifetimes, we were limited in 
our ability to determine when they last injected drugs. It is not known to what extent social 
desirability bias may have affected participant responses around injection drug use and 
current PrEP use, nor whether participants who refused in-field HIV testing differed from 
participants who completed in-field testing. The With regard to the PrEP awareness 
question, we focused on PrEP use for sexual behavior-related risks, and not for injection 
drug use-related risks. The questions regarding methamphetamine, cocaine, and opioid use, 
as well as injection drug use, were for lifetime use. In the future, measuring recent use (e.g., 
last six months) is warranted.
4.2 Conclusion
We found that 3.6% of BMSM attending Black Pride events in six cities across the U.S. 
between 2014 and 2017 had injected drugs. We found a high prevalence of unknown HIV 
infection (25%) among our sample. In addition, BMSM who injected drugs were marginally 
more likely to test positive for HIV than BMSM who did not inject drugs, despite self-
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reporting significantly higher rates of current PrEP use. There was no difference in HIV 
prevalence based on in-field testing for BMSM who injected drugs by self-reported current 
PrEP use. Future research regarding PrEP among BMSM who inject drugs is warranted, 
including an examination of individual and structural barriers to accessing, engaging, and 
remaining in PrEP care.
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• 3.6% of BMSM injected drugs in their lifetime.
• 58.5% of BMSM who injected drugs reported sharing syringes in the past 6 
months.
• 31.7% of BMSM who injected drugs had an unknown HIV positive status.
• BMSM who injected drugs had higher levels of PrEP use than BMSM who 
never injected.
• Among BMSM who injected drugs, current PrEP was not associated with 
HIV status.
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Table 1.
Drug use and socio-demographic characteristics among BMSM attending Black Pride events, 2014–2017.
Category
Overall PWID Non-PWID χ2 Statistic
p-value)
N (%) N (%) N (%)
Overall 3429 (100) 123 (100) 3306 (100) -
Lifetime Drug Use
Opioids 94 (2.7) 43 (35.0) 51 (1.5) 496.7 < 0.001
 Methamphetamine 54 (1.6) 32 (26.0) 22 (0.7) 491.7 < 0.001
 Cocaine 176 (5.1) 54 (43.9) 122 (3.7) 393.8 < 0.001
Shared Syringes in the Past 6 Months
1 - 72 (58.5) -
Tested for HIV in the Past 6 Months 2119 (61.8) 81 (65.9) 2068 (61.6) .890 0.346
Experience with HIV PrEP
2 85.5 < 0.001
 Unaware of PrEP 1599 (46.6) 57 (46.3) 1542 (46.6)
 Aware but not currently using 1520 (44.3) 26 (21.1) 1494 (45.2)
 Aware and currently using 310 (9.0) 40 (32.5) 270 (8.2)











Age, Med (IQR) 27 (24–34) 31 (25–40) 27 (24–33) Z=−4.33 < 0.0013
# Male Partners, Med (IQR) 3 (1–5) 5 (3–8) 3 (1–5) Z=−4.33 < 0.0013
# Female Partners, Med (IQR) 0 (0–1) 2 (0–5) 0 (0–1) Z=−4.33 < 0.0013
1
Percentages of syringe sharing were calculated from the sub-sample of persons who had ever injected drugs.
2
Participants who had never heard of PrEP were not asked questions about their current use.
Those who were aware of PrEP reported on their current use of PrEP.
3
Wilcoxon rank sum test.
Abbreviations: PWID: person who injects drugs. PrEP: pre-exposure prophylaxis. IQR: interquartile range. Med: median.
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Table 2.
Adjusted prevalence ratios of sociodemographic characteristics, substance use history, and sexual behavior 
with current PrEP use among a sample of BMSM attending Black Pride events, 2014–2017.
Covariate Adjusted PR 95% CI p
Lifetime Injection Drug Use 3.57 2.36, 5.41 < 0.001
Age 0.98 0.97, 0.99 0.27
Annual Income 1.61 1.28, 2.03 < 0.001
Lifetime Drug Use
 Opioids 0.82 0.40, 1.65 0.58
 Methamphetamine 1.51 0.91, 2.49 0.11
 Cocaine 1.49 0.71, 3.16 0.29
# Male Partners 1.02 1.01, 1.03 < 0.001
# Female Partners 1.00 0.98, 1.03 0.57
Abbreviations: CI = confidence interval, PR = prevalence ratio.
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